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RV failureAbstract Behc¸et’sdisease (BD) is a chronic, multisystem vasculitis. It is categorized under variable
vessel vasculitis in the new Chapel Hill nomenclature as it involves blood vessels of any type and
size. It is characterized by relapsing aphthous ulcers commonly occurring in the oral mucosa and
genitalia with ocular involvement. Other organ systems may be involved any time throughout
the course of the disease. The exact cause is unknown. However, combination of genetic and envi-
ronmental factors is likely to play a role.
Cardiac involvement may occur in the form of intracardiac thrombus, endocarditis, myocarditis,
pericarditis, endomyocardial fibrosis, coronary arteritis, myocardial infarction, and valvular dis-
ease.
We present a case of Angio-Behc¸et in a 46-year-old African male with severe cardiovascular
involvement including pulmonary artery hypertension (PAH), right ventricular failure and left ven-
tricular diastolic dysfunction diagnosed after 2 episodes of symptomatic ischemic stroke resulting
from complete occlusion of the right internal carotid artery (ICA) up to its intracranial portion.
Immunosuppressive and anticoagulant therapies have induced improvement in cardiac manifesta-
tions. Nevertheless, prompt recognition of the primarily vascular manifestation of BD without
mucocutaneous manifestations was responsible for considerable delay that did not afford surgical
therapy for the carotid occlusion.
 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Behc¸et’s disease (BD) is a chronic, multisystem vasculitis. It is
categorized under variable vessel vasculitis in the new Chapel
Hill nomenclature as it involves blood vessels of any type
and size.1 It is characterized by relapsing aphthous ulcerse cardio-
Figure 1 Echocardiography showing right chamber enlargement
(arrow) and Doppler measurement of peak velocity of tricuspid
regurgitation used for estimation of pulmonary artery systolic
pressure.
Figure 2 CT Scan: multiple rib fractures.
2 B.D. Marie et al.commonly occurring in the oral mucosa and genitalia with
ocular involvement.2–4 Other organ systems may be involved
any time throughout the course of the disease.
The exact cause is unknown. However, combination of
genetic and environmental factors is likely to play a role. Some
researchers believe that an environmental factor or infection,
such as a virus, bacterium, or pollution, may trigger an autoin-
flammatory reaction within people who have certain disease
susceptibility genes.5–7
Behc¸et’s disease has a worldwide distribution. However, it
is observed commonly among populations living along the his-
toric Silk Road (Japan, China, Turkey and Iran). That is also
why it was given the name ‘‘Silk Road Disease”.8 It is most
common in Turkey with estimated prevalence of 421 per
100,000 population.9 It remains rare in other countries such
as the Americas and African countries.8
To date, Behc¸et’s Disease remains a clinical diagnosis based
on its disease manifestations. There is no relevant biological
test for diagnosis.
Vasculo-Behc¸et disease (vasculo-BD) is one of the most sev-
ere and life-threatening facets of BD which predominantly
appears in large blood vessels.10
Cardiac involvement may occur in the form of intracardiac
thrombus, endocarditis, myocarditis, pericarditis, endomy-
ocardial fibrosis, coronary arteritis, myocardial infarction,
and valvular disease.4
We herein report a case of Angio-Behc¸et with severe cardio-
vascular involvement discovered after 2 episodes of symp-
tomatic ischemic stroke.
2. Case report
A 46-year-old previously healthy male was admitted in 2015
for evaluation of recurrent ischemic strokes happened in
2009 and 2010, fatigue and lack of energy since 2013.
Further detailed medical history revealed that the patient
had a history of traffic Road accident in 2008 with multiple
rib fractures and hemothorax. Recurrent oral aphthae started
1 year later after the accident and a history of fertility
abnormalities.
Physical examination on admission determined Dyspnea on
exertion (NYHA III), murmur of tricuspid regurgitation,
accentuated pulmonic component of the second heart sound,
also referred to as P2, and external signs of right heart failure
(peripheral edema, elevated jugular venous pulsations and
hepatomegaly).
It was noted also a small right pleural effusion and ataxia.
Oral aphthae, scrotal scar and erythema nodosum in the
lower extremities were present.
Laboratory test showed an increased level of inflammatory
markers such as C-reactive protein (CRP) and erythrocyte sed-
imentation rate (ESR).
On ECG, there was a complete right bundle branch block.
The transthoracic echocardiography performed showed
that the right-sided cardiac structures were larger than normal
with severe tricuspid regurgitation and pulmonary artery pres-
sure was 70 mmHg (Fig. 1). It was also noted, signs of left ven-
tricular diastolic dysfunction with preserved systolic function.
Spiral CT scanner performed in emergency excluded acute
or chronic pulmonary embolism, but showed multiple consol-
idated rib fractures (Fig. 2).Please cite this article in press as: Marie BD et al. Recurrent symptomatic ischemic s
vascular involvement, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.ehj.201The cerebral Scanner was normal.
Cervical ultrasound showed a complete occlusion of the
right internal carotid artery (ICA) from the middle part of
the common carotid artery (CCA) up to the submandibular
part of the ICA.
Neuro-vascular angiography showed the extend of the
occlusion up to the intracranial portion of the ICA
(Fig. 3a and b). The circle of Willis was not involved (Fig. 4).
The diagnosis of Angio-Behc¸et was retained according to
the criteria for diagnosis of BD proposed by the International
Group Study (ISG) for BD.6
As consequence, in addition to diuretics, statins and AVK,
the patient received corticosteroids and colchicine.
Clinical course was good with substantial improvement of
mucocutaneous and cardiac symptoms.
Improvement of dyspnea was noted but still present
(NYHA 1-2) and echography findings remained unchanged
except pulmonary artery pressure which was 60 mmhg in
2 months follow-up.troke in a 46-year-old African male revealing Angio-Behc¸et with severe cardio-
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Figure 3 (a and b) Angiography: complete occlusion of the right ICA (LCA= left carotid artery, RCA=right carotid artery).
Figure 4 Angiography: intact circle of Willis.
Recurrent symptomatic ischemic stroke in a 46-year-old African male 3The patient was discharged from hospital on the same treat-
ment since there were no possibilities of surgery for his carotid
occlusion because of its extension up to the intracranial
portion.
3. Discussion
Behc¸et disease is a multifactory disorder. There have been
many theories about its origin, including viral etiology, bacte-
rial infections, autoimmuno mechanisms and genetic
predispositions.
Although the medical understanding of this disease has
been advanced, its cause is still unknown.4,11 In our patient,
it is suggested that his past medical history of road trafficPlease cite this article in press as: Marie BD et al. Recurrent symptomatic ischemic s
vascular involvement, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.ehj.2016accident with rib fractures and hemothorax and his long stay
in intensive care unit, may constitute the triggering event.
Due to the lack of specific clinical and laboratory diagnosis
tests, several sets of diagnostic criteria have ben proposed. Of
these are the criteria of BD committee of Japan.12
Over the years, five major independent sets of criteria have
been used for diagnosing BD, each characterized by its own
clinical features and frequencies, as well as nature of criteria
that should be met in order for the diagnosis to be positive.6,13
All required a confirmation of the three major symptoms ini-
tially described by Behc¸et as a separate clinical entity (oral
ulceration, genital ulceration, and eye lesions). The Interna-
tional Study Group (ISG) for BD proposed the main interna-
tional standards for diagnosing BD.6 These criteria, published
in 1990 and last updated in 2013, provided simpler means for
diagnosis of BD, excluded rare and subjective features, and
showed more specificity with little or no loss of sensitivity to
previously used tools.4,14
In 2004, Lawton et al. conducted a study in an attempt to
define a set of clinical features that may be used as a standard
index for measurement of BD activity.15
The incidence of vascular involvement in BD varies from
7% to 29%.16 Cardiac involvement is present in 0.14% of
patients.16 Intraventricular thrombosis, regurgitant valvular
heart diseases, coronary arteries aneurysms, and myocardial
infarction are some of the reported manifestations of cardiac
involvement in such disease.17 Sporadic cases of myocarditis,
pericarditis, aortic aneurysms, and conductive tissue disorders
were also reported during BD.18 In such a disease, arterial
involvement is less frequent than venous lesions. However, it
is markedly more dreadful, as it was correlated with an impor-
tant morbimortality. There are two types of arterial manifesta-
tions: occlusive and more commonly aneurismal lesions.19
Occlusive and stenotic lesions involve not only great vessels,
but also vasa vasorum. Frequently involved arteries in decreas-
ing order are pulmonary artery, femoral, popliteal, subclavian,
and carotid arteries.troke in a 46-year-old African male revealing Angio-Behc¸et with severe cardio-
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4 B.D. Marie et al.There are two mechanisms to explain thrombosis during
Angio-Behc¸et: vasculitis and hypercoagulable state. BD’s vas-
culitis involves usually all layers of a vessel and is characterized
by the presence of lymphocytic infiltrate during the acute
phase. At an advanced stage, an important fibrotic and scar-
ring reaction develops.20,21 Hypercoagulable state observed
during BD is thought to be due to inhibition of fibrinolysis
on the one hand and due to increased platelet aggregation
on the other hand. The latter had been explained by endothe-
lial dysfunction leading to increased production of von Wille-
brand factor and decreased levels of prostacyclin (PGI2).21,22
Increased production of fibrinogen and factor VIII could also
represent other etiological factors explaining hypercoagulable
state.23 In our case, both hypercoagulable state and vasculitis
seemed to be involved in the ICA occlusion.
The annual risk of a major stroke varies from 1% to 3.2%
in cases of luminal narrowing ranging from 50% to 99%.24–26
This risk remains almost stable over a long period of time.25
An increasing degree of luminal narrowing is associated with
an increasing risk of stroke in asymptomatic ICA stenosis.
For every 10% increase in luminal narrowing, the stroke risk
increases by nearly 31%, or 0.6% per year.26 After an ischemic
event in the territory of the stenosed ICA, the annual major
stroke risk increases to between 8% and 13%.27,28 In symp-
tomatic patients too, the degree of stenosis modulates the risk
of stroke; for every 10% increase in ICA luminal narrowing,
the stroke risk increases by approximately 10% (absolute risk
increase of approximately 0.4%).26 The annual risk of major
ipsilateral stroke associated with ICA occlusion is approxi-
mately between 1.9% and 3.8% per year.26
Pulmonary hypertension in BD can be explained by 2 dif-
ferent mechanisms: complication of a connective tissue disease
and following thrombo-embolism.
Pulmonary hypertension is a common complication of con-
nective tissue disease (CTD) and confers a worse prognosis.
Connective tissue disease associated pulmonary hypertension
(CTD-PH) occurs most often with systemic sclerosis (SSc)
but may also complicate mixed connective tissue disease
(MCTD). Although the pathogenesis leading to CTD-PH
may vary, the clinical presentation, treatment, and pathologi-
cal lesions are often similar to those observed in idiopathic pul-
monary arterial hypertension (IPAH), with intimal and medial
thickening in small and medium-sized pulmonary arteries and
plexiform lesions in some cases.29 Fewer studies have examined
the occurrence of pulmonary hypertension complicating
MCTD, but one study with 26 patients found pulmonary
hypertension in 7 patients (27%).30 Others have found evi-
dence of pulmonary hypertension in as many as 75% of
patients with MCTD.31 Pulmonary hypertension has also been
reported as the most frequent disease-associated cause of death
in patients with MCTD.32
Chronic thromboembolic pulmonary hypertension
(CTEPH) represents a unique cause of secondary pulmonary
hypertension by virtue of its potentially remedial nature.
It was originally thought that 0.1% to 1% of patients who
suffered from pulmonary embolism would subsequently
develop pulmonary hypertension.33 However, more data sug-
gest that 0.8% to as many as 3.1% of patients may develop
CTEPH after an initial episode of pulmonary embolism,34,35
with an even higher occurrence after recurrent thromboem-
bolic events.34Please cite this article in press as: Marie BD et al. Recurrent symptomatic ischemic s
vascular involvement, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.ehj.201Although the mechanisms by which patients develop
CTEPH are not fully understood, incomplete resolution of
pulmonary emboli rather than in situ thrombosis of the pul-
monary arteries appears to be the major contributor.36,37
Approximately 50% of patients presenting with acute
symptomatic pulmonary embolism have echocardiographic
evidence of right ventricular dysfunction.38 Afterward,
echocardiographic and pulmonary perfusion scan abnormali-
ties typically stabilize over four to six weeks.39,40
In our patient the 2 mechanisms could be involved.
The main cause of morbidity and mortality in PAH is not
injury to the lung, but rather progressive right ventricular
(RV) dysfunction.
In most cases of PAH, PA pressure escalates faster than the
RV can adapt. Although many patients develop significant RV
hypertrophy, increased myocardial cell size and strength give
way to apoptosis, fibrosis, and decreased contractility. The
net result is a transition from a hypertrophic RV with pre-
served systolic function to a dilated, hypokinetic ventricle.
As the RV enlarges, wall tension rises and free wall thickness
decreases. The expanding RV widens the tricuspid annulus
and causes chordal traction and tethering of the tricuspid leaf-
lets, worsening tricuspid regurgitation and further compromis-
ing RV function. RV end-diastolic pressure rises, forcing the
interventricular septum toward the LV during diastole and
compromising LV filling.
Another finding in our patient was fertility abnormalities.
Decreased fertility potential is not unusual among patients of
both genders with rheumatic diseases, particularly in
women.41,42
The reproduction potential of these male patients is
impaired by the disease directly in the testicular tissue or by
immunosuppressive therapy. A recent study evaluated fertility
outcome of a larger retrospective cohort of BD patient’s com-
pared to a control Group.43 They observed that 23 out of 130
subjects had infertility and the most common etiology was
varicocele. In contrast, none of the 14 men with BD assessed
for AntiSperm Antibodies (ASA) had antisperm antibodies.44
The evaluation of male subjects should rely on careful med-
ical history, complete physical examination, semen analysis
and sexual hormone profile.
The prognosis of mucocutaneous involvement in BD is gen-
erally good.45 Vascular involvement represents the most
important cause of mortality.46 Neurological involvement is
progressive among most patients, and is sometimes fatal.
Annual mortality in BD varies between 2% and 4%. The most
common causes of mortality are rupture of vascular
aneurysms.7
Overall survival in BD patients with cardiac involvement is
poorer than in those without. Complete remission of cardiac
involvement has been associated with the use of immunosup-
pressants, colchicine, and anticoagulants.46
4. Conclusion
BD is a disease with multi-organ involvement and thus shows
signs and symptoms in many systems. Angio-Behc¸et is one of
the most severe and life-threatening facets of BD which pre-
dominantly appears in large blood vessels. Several cardiac
manifestations may coincide in one patient. Cardiologiststroke in a 46-year-old African male revealing Angio-Behc¸et with severe cardio-
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Recurrent symptomatic ischemic stroke in a 46-year-old African male 5should always bear in mind the potential threats of symp-
tomatic cardiovascular involvement in BD and consider diag-
nostic measures for its timely detection. The prognosis of
cardiac lesions is poorer than that of lesions in other organs
involved in BD, but anticoagulation, immunosuppressant
agents, and colchicine seem to improve the prognosis of car-
diac manifestations in BD.
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